Multinational drug firm Fresenius Kabi, which has acquired Dabur Pharma, today said it would invest up to 30 million euro in the next 2-3 years in doubling the latter's active pharmaceutical ingredients manufacturing facility in Kolkata.
"We are planning to invest 10-30 million euros in doubling the capacity of API manufacturing facility of Dabur Pharma, located in Kolkata," Fresenius Kabi President and CEO Rainer Baule told reporters here.
The company also said it was looking to offload about one per cent stake in Dabur Pharma as per the SEBI guidelines.
"We are interested in strategic buyer to offload the one per cent additional stake as per the necessary regulation of SEBI and we are talking to number of people for that," Baule added.
Yesterday, Dabur Pharma said Fresenius Kabi (Singapore) Pte Ltd (Fresenius) had acquired 90.89 per cent stake in the firm.
Earlier, Fresenius had acquired 73.27 per cent in Dabur Pharma from its promoters and certain other shareholders in April. Further, Fresenius made an open offer for an additional 20 per cent stake in the firm.